Translational Challenges in Atrial Fibrillation
Open accessThe DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Abstract
Atrial fibrillation (AF) is the most common sustained heart rhythm disorder and is associated with substantial morbidity and mortality. Current treatment options for AF have significant limitations. Basic research has provided information on mechanisms relevant to the management of AF and promises to contribute significantly to future advances, yet many important translational challenges remain. Here, we analyze the therapeutic limitations for which improvement is needed, consider the translational opportunities presented by recent scientific and technological developments, and attempt to look into the future of where these may lead. We first review the limitations of current AF management, with a focus on rhythm control therapy. These include arrhythmia complications, progression to advanced treatment-resistant forms, insufficient effectiveness of available therapeutic options, adverse consequences of therapy, and difficulties in new therapeutic development. The translational challenges in addressing these shortcomings are then addressed, including (1) defining actionable patient-specific arrhythmia mechanisms to enable personalized therapy; (2) identifying and treating key dynamic modulators controlling AF initiation and progression; (3) achieving atrial-restricted targeting of specific molecular arrhythmia mechanisms; and (4) clarifying the response of the substrate to interventions. For each of these, we describe the translational goal and the opportunities created by recent advances in cardiac imaging, computational modeling, rhythm monitoring, ablation technology, and preclinical studies in human samples and animal models. Finally, we consider the prospects for future solutions that might appreciably improve our ability to understand and manage the arrhythmia over the years to come.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease
Ridker, P. M., Everett, B. M., Thuren, T., MacFadyen, J. G., Chang, W. H., Ballantyne, C., Fonseca, F., Nicolau, J., Koenig, W., Anker, S. D., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1707914 · Cited by 9,482
A comparison of rate control and rhythm control in patients with atrial fibrillation
(2002) · New England Journal of Medicine · doi:10.1056/nejmoa021328 · Cited by 4,405
Approaches to catheter ablation for persistent atrial fibrillation
Verma, A., Jiang, C.-Y., Betts, T. R., Chen, J., Deisenhofer, I., Mantovan, R., Macle, L., Morillo, C. A., Haverkamp, W., Weerasooriya, R., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1408288 · Cited by 2,339
Rhythm control versus rate control for atrial fibrillation and heart failure
Roy, D., Talajic, M., Nattel, S., Wyse, D. G., Dorian, P., Lee, K. L., Bourassa, M. G., Arnold, J. M. O., Buxton, A. E., Camm, A. J., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0708789 · Cited by 1,585
Marrouche, N. F., Wilber, D., Hindricks, G., Jais, P., Akoum, N., Marchlinski, F., Kholmovski, E., Burgon, N., Hu, N., Mont, L., et al. (2014) · JAMA · doi:10.1001/jama.2014.3 · Cited by 1,473
Pathophysiological mechanisms of atrial fibrillation: a translational appraisal
Schotten, U., Verheule, S., Kirchhof, P., & Goette, A. (2011) · Physiological Reviews · doi:10.1152/physrev.00031.2009 · Cited by 1,273
A highly durable RNAi therapeutic inhibitor of PCSK9
Fitzgerald, K., White, S., Borodovsky, A., Bettencourt, B. R., Strahs, A., Clausen, V., Wijngaard, P., Horton, J. D., Taubel, J., Brooks, A., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1609243 · Cited by 768
Driver domains in persistent atrial fibrillation
Haissaguerre, M., Hocini, M., Denis, A., Shah, A. J., Komatsu, Y., Yamashita, S., Daly, M., Amraoui, S., Zellerhoff, S., Picat, M.-Q., et al. (2014) · Circulation · doi:10.1161/circulationaha.113.005421 · Cited by 734
Radiofrequency ablation as initial therapy in paroxysmal atrial fibrillation
Cosedis Nielsen, J., Johannessen, A., Raatikainen, P., Hindricks, G., Walfridsson, H., Kongstad, O., Pehrson, S., Englund, A., Hartikainen, J., Mortensen, L. S., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1113566 · Cited by 720
Morillo, C. A., Verma, A., Connolly, S. J., Kuck, K. H., Nair, G. M., Champagne, J., Sterns, L. D., Beresh, H., Healey, J. S., Natale, A., et al. (2014) · JAMA · doi:10.1001/jama.2014.467 · Cited by 667
Cited by
Postoperative atrial fibrillation: mechanisms, manifestations and management
Dobrev, D., Aguilar, M., Heijman, J., Guichard, J.-B., & Nattel, S. (2019) · Nature Reviews Cardiology · doi:10.1038/s41569-019-0166-5 · Cited by 608
Self-citationMolecular Basis of Atrial Fibrillation Pathophysiology and Therapy: A Translational Perspective
Nattel, S., Heijman, J., Zhou, L., & Dobrev, D. (2020) · Circulation Research · doi:10.1161/circresaha.120.316363 · Cited by 440
Self-citationDobrev, D., Heijman, J., Hiram, R., Li, N., & Nattel, S. (2023) · Nature Reviews Cardiology · doi:10.1038/s41569-022-00759-w · Cited by 268
Self-citationAtrial fibrillation detection from wrist photoplethysmography signals using smartwatches
Bashar, S. K., Han, D., Hajeb-Mohammadalipour, S., Ding, E., Whitcomb, C., McManus, D. D., & Chon, K. H. (2019) · Scientific Reports · doi:10.1038/s41598-019-49092-2 · Cited by 120
Metadata
- Authors
- Heijman, J., Guichard, J.-B., Dobrev, D., & Nattel, S.
- Venue
- Circulation Research
- Published
- 2018-03-02
- Volume
- 122
- Issue
- 5
- Pages
- 752-773
- ISSN
- 0009-7330 (ISSN-L)
- 1524-4571
- OpenAlex
- W2793542784
- Cited by
- 165
- References
- 24
- FWCI
- 14.97
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Translational Challenges in Atrial Fibrillation. https://app.cochat.ai/papers/10.1161/circresaha.117.311081
- The paper
- Heijman, J., Guichard, J.-B., Dobrev, D., & Nattel, S. (2018). Translational Challenges in Atrial Fibrillation. Circulation Research. https://doi.org/10.1161/circresaha.117.311081
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.